Who are RP-G28's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ALGRX 3268, QA108 granules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rp-g28.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

RP-G28 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RP-G28 (RP-G28) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microbiome modulator. Area: Gastroenterology / Metabolic Disease.

phase 3 Microbiome modulator Gastroenterology / Metabolic Disease Small molecule Live · refreshed every 30 min

Target snapshot

RP-G28 (RP-G28) — Ritter Pharmaceuticals, Inc.. RP-G28 is a non-systemic oral therapeutic that modulates the gut microbiome to improve metabolic and immune function.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RP-G28 TARGET	RP-G28	Ritter Pharmaceuticals, Inc.	phase 3	Microbiome modulator
ALGRX 3268	ALGRX 3268	AlgoRx Pharmaceuticals	phase 3	Microbiome modulator	Alginate lyase
QA108 granules	QA108 granules	Smilebiotek Zhuhai Limited	phase 3	Gut microbiome modulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microbiome modulator class)

AlgoRx Pharmaceuticals · 1 drug in this class
Ritter Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RP-G28 — Competitive Intelligence Brief. https://druglandscape.com/ci/rp-g28. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing